Tyr1213
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr1213  -  VEGFR1 (human)

Site Information
GsSDDVRyVNAFKFM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448209
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 10 ) , mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 ) , mutation of modification site ( 8 , 9 , 10 ) , phospho-antibody ( 3 , 10 ) , phosphoamino acid analysis ( 10 ) , phosphopeptide mapping ( 10 ) , western blotting ( 3 , 10 )
Disease tissue studied:
brain cancer ( 3 ) , glioblastoma ( 3 ) , glioma ( 3 ) , kidney cancer ( 5 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 4 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) ( 10 ) , HMEC (endothelial) ( 3 ) , kidney ( 5 ) , lung ( 4 ) , MS1 (endothelial) ( 9 ) , PAE (endothelial) ( 8 ) , SF9 ( 10 ) , U87MG (glial) ( 3 )

Upstream Regulation
Regulatory protein:
uPA (human) ( 3 ) , uPAR (human) ( 3 )
Putative in vivo kinases:
VEGFR1 (human) ( 10 )
Kinases, in vitro:
VEGFR1 (human) ( 9 , 10 )

Downstream Regulation
Effects of modification on VEGFR1:
enzymatic activity, induced ( 8 ) , molecular association, regulation ( 9 )
Induce interaction with:
GRB2 (mouse) ( 9 ) , PLCG1 (mouse) ( 9 ) , SHP-2 (mouse) ( 9 )

References 

1

Rikova K (2012) CST Curation Set: 14270; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 1mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

2

Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

3

Raghu H, et al. (2012) uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells. Mol Oncol 6, 33-47
22177802   Curated Info

4

Ren H (2009) CST Curation Set: 8106; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Tucker M (2009) CST Curation Set: 7686; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Farnsworth C (2007) CST Curation Set: 3377; Year: 2007; Biosample/Treatment: cell line, purified protein/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Farnsworth C (2007) CST Curation Set: 3378; Year: 2007; Biosample/Treatment: cell line, purified protein/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Ito N, Huang K, Claesson-Welsh L (2001) Signal transduction by VEGF receptor-1 wild type and mutant proteins. Cell Signal 13, 849-54
11583921   Curated Info

9

Ito N, Wernstedt C, Engström U, Claesson-Welsh L (1998) Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem 273, 23410-8
9722576   Curated Info

10

Sawano A, Takahashi T, Yamaguchi S, Shibuya M (1997) The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma. Biochem Biophys Res Commun 238, 487-91
9299537   Curated Info